Global and United States GLP-1 Agonist Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States GLP-1 Agonist Market Report & Forecast 2024-2034
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
Market Analysis and InsightsGlobal and United States GLP-1 Agonist Market
This report focuses on global and United States GLP-1 Agonist market, also covers the segmentation data of other regions in regional level and county level.
The global GLP-1 Agonist revenue was US$ 20600 million in 2022 and is forecast to a readjusted size of US$ 44730 million by 2034 with a CAGR of 16.6% during the forecast period (2024-2034).
In United States the GLP-1 Agonist revenue is expected to grow from US$ million in 2022 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of GLP-1 Agonist include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. The global five biggest players hold a share of % in 2022.
Global GLP-1 Agonist Scope and Market Size
GLP-1 Agonist market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global GLP-1 Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the GLP-1 Agonist market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces GLP-1 Agonist definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of GLP-1 Agonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of GLP-1 Agonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Agonist sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States GLP-1 Agonist Market
This report focuses on global and United States GLP-1 Agonist market, also covers the segmentation data of other regions in regional level and county level.
The global GLP-1 Agonist revenue was US$ 20600 million in 2022 and is forecast to a readjusted size of US$ 44730 million by 2034 with a CAGR of 16.6% during the forecast period (2024-2034).
In United States the GLP-1 Agonist revenue is expected to grow from US$ million in 2022 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of GLP-1 Agonist include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. The global five biggest players hold a share of % in 2022.
Global GLP-1 Agonist Scope and Market Size
GLP-1 Agonist market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global GLP-1 Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the GLP-1 Agonist market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Segment by Application
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces GLP-1 Agonist definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of GLP-1 Agonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of GLP-1 Agonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Agonist sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices